mRNA-1345
Phase 1Active 1 views this week 0 watching
0
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus, Human Metapneumovirus
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Trial Timeline
Feb 15, 2023 → Aug 31, 2026
NCT ID
NCT05743881About mRNA-1345
mRNA-1345 is a phase 1 stage product being developed by Moderna for Respiratory Syncytial Virus, Human Metapneumovirus. The current trial status is active. This product is registered under clinical trial identifier NCT05743881. Target conditions include Respiratory Syncytial Virus, Human Metapneumovirus.
What happened to similar drugs?
4 of 20 similar drugs in Respiratory Syncytial Virus, Human Metapneumovirus were approved
Approved (4) Terminated (1) Active (15)
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07117487 | Phase 3 | Active |
| NCT06143046 | Phase 2 | Active |
| NCT06097299 | Phase 2 | Completed |
| NCT06067230 | Phase 3 | Active |
| NCT06060457 | Phase 3 | Completed |
| NCT05743881 | Phase 1 | Active |
| NCT05572658 | Preclinical | Completed |
| NCT05330975 | Phase 3 | Completed |
| NCT05127434 | Phase 3 | Completed |
| NCT04528719 | Phase 1 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus, Human Metapneumovirus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Preclinical | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 44 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 30 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| YMC026 + Placebo | Yuhan | Approved | 43 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 35 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 32 |
| S-337395 + Placebo | Shionogi | Phase 2 | 42 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 35 |